Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 2
1999 2
2000 3
2001 3
2002 3
2003 2
2004 5
2005 6
2006 5
2007 3
2008 1
2009 3
2010 7
2011 6
2012 3
2013 5
2014 10
2015 8
2016 10
2017 6
2018 12
2019 9
2020 6
2021 6
2022 6
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24955784

111 results

Results by year

Filters applied: . Clear all
Page 1
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC. Sanchorawala V, et al. Biol Blood Marrow Transplant. 2015 Aug;21(8):1445-51. doi: 10.1016/j.bbmt.2015.04.001. Epub 2015 Apr 6. Biol Blood Marrow Transplant. 2015. PMID: 25858810 Free article. Clinical Trial.
Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA. Sidiqi MH, et al. Bone Marrow Transplant. 2019 Jul;54(7):1077-1081. doi: 10.1038/s41409-018-0388-x. Epub 2018 Nov 2. Bone Marrow Transplant. 2019. PMID: 30390060
Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK, Brauneis D, Shelton AC, Quillen K, Sarosiek S, Sloan JM, Sanchorawala V. Gupta VK, et al. Biol Blood Marrow Transplant. 2019 May;25(5):e169-e173. doi: 10.1016/j.bbmt.2019.01.007. Epub 2019 Jan 11. Biol Blood Marrow Transplant. 2019. PMID: 30639823 Free article. Clinical Trial.
Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Badar T, et al. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213. doi: 10.1038/s41409-018-0178-5. Epub 2018 Apr 20. Bone Marrow Transplant. 2018. PMID: 29679076 No abstract available.
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Cibeira MT, et al. Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9. Blood. 2011. PMID: 21828140 Free PMC article.
111 results